Table 2.

PARP inhibitors in ovarian cancer–G3/G4 Adverse Events

	OLA (%)	OLA+CED (%)	OLA+CT (%)	VEL (%)	VEL+CHT (%)	NIR (%)	RUC (%)	INI (%)
Nausea	0–8	5	1	1	0	0	3	0
Vomiting	0–4	0	0	0	0	0.5	0	0
Diarrhoea	0–5	23	0	0	0	0	0	8.3
Dehydration	0	0	0	0	0.4	0	0	0
Hyponatremia	0	0	0	0	0.7	0	0	8.3
Abdominal pain	0–8	0	0	0	0	0	1	0
Headache	0	5	1	0	0	0	0	0
Constipation	0–2	0	0	0	0	0	0	0
Decreased appetite	0–2	0	1	0	0	0.5	0	0
Upper abdominal pain	0	0	0	0	0	0	1	0
Arthralgia	0–1	0	0	0	0	0	0	0
Back pain	0–2	0	0	0	0	0	0	0
Asthenia/fatigue	3–11	27	7	0	0	1.5	6	0
Abdominal distension	0–3	0	0	0	0	0	0	0
Leucopenia	0–2	0	5	0.5	0.7	0	0	0
Neutropenia	0–9	0	43	0.5	0.7	1.5	0	0
Lymphopenia	0–4	0	0	0	4.8	0.5	0	8.3
Thrombocytopenia	0	0	6	0.5	0.4	3.5	0	0
Anemia	0–20	0	9	0	0.7	3	0	0
Hypertension	0	41	0	0	0	0	0	8.3
Peripheral sensory neuropathy	2	0	0	0	0	0	0	0
Drug hypersensitivity	0	0	5	0	0	0	0	0
Dyspnea	4	0	0	0	0	0	0	0
Increased AST	0	0	0	0	0	0	0	8.3
Increased ALT	0	0	0	0	0	0	0	16.7
Increased activated partial thromboplastin time	0	0	0	0	0	0	0	8.3
Hyperbilirubinemia	0	0	0	0	0	0	0	8.3
Increased alkaline phosphatase	0	0	0	0	0	0	0	16.7
Increased international normalized ratio	0	0	0	0	0	0	0	16.7
Malignant pleural effusion	0	0	0	0	0	0	0	8.3
Gastro-oesophageal reflux disease	4	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	8.3

OLA Olaparib, VEL veliparib, CED cediranib, RUC rucaparib, NIR niraparib, PLA placebo, unk unknown, mt mutated, wt wild type, Pts patients, NR not reported, P Paclitaxel, CBDC Carboplatin, Res platinum resistant, Ref platinum refractory, CT chemotherapy